BRAF and melanoma: Combined inhibition of BRAF (by vemurafenib) and HDAC (by 4-phenylbutyrate) upregulated MC1R expression in BRAF-mutant melanoma cells leading to an increased response of BRAFV600E A2058 melanoma-bearing mice to the MC1R-targeting radiolabeled peptide [212Pb]DOTA-MC1L [Table 3][109].